Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 5/20 | 0.68 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.68 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.66 |
| ▸ | LTA4H | P09960 | 7/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741674 | 1.00 | PSMB1 (0.68) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL228735 | 0.99 | PSMB1 (0.66) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL228395 | 0.99 | PSMB1 (0.66) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL7240783 | 0.98 | PSMB1 (0.65) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL7629621 | 0.95 | HRH3 (0.63) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL3718784 | 0.93 | HRH3 (0.69) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL2852389 | 0.93 | HRH3 (0.69) | KDM4EHRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2852644 | 0.92 | HRH3 (0.68) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL11154787 | 0.87 | PSMB1 (0.66) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL4092312 | 0.87 | PSMB1 (0.66) | PSMB1PSMB5PSMB2KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | PSMB1 500/4885PSMB5 702/4885PSMB2 875/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | PSMB1 658/4885PSMB5 695/4885PSMB2 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.